Explore the exciting world of Editas Medicine (EDIT -4.12%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of April 9, 2025. The video was published on May 15, 2025.
S&P 500
5,973.41
+0.0%
+$2.60
DJI
42,455.35
+0.1%
+$27.61
NASDAQ
19,528.06
+0.3%
+$67.57
Bitcoin
104,219.00
-0.5%
-513.18
AAPL
$202.63
-0.1%
-$0.19
AMZN
$210.70
+1.7%
+$3.48
GOOG
$171.98
+1.5%
+$2.59
META
$693.55
+0.8%
+$5.60
MSFT
$467.27
+0.7%
+$3.40
NVDA
$141.98
+0.0%
+$0.06
TSLA
$318.40
-4.1%
-$13.65
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Editas Medicine: A Cautionary Tale for Investors
By Motley Fool YouTube
–
May 15, 2025 at 7:30PM
NASDAQ: EDIT
Editas Medicine
Market Cap
$152M
Today's Change
(-4.12%) -$0.07
Current Price
$1.75
Price as of June 5, 2025, 10:49 a.m. ET
Anand Chokkavelu, CFA has positions in Editas Medicine. Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Editas Medicine. The Motley Fool has a disclosure policy.
Stocks Mentioned
Editas Medicine
EDIT
$1.75
(-4.12%)
$0.07
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
1 Stock Down 97% That Could Double, According to Wall Street
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
1 Beaten-Down Stock With 55% Upside, According to Wall Street
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.